Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin

Journal of Bone Oncology

Volumn 3, Issue 1, 2014, Pages 18-24

  Benad Mehner, Peggy ^a   Thiele, Stefanie ^a   Rachner, Tilman D ^a   Göbel, Andy ^a   Rauner, Martina ^a   Hofbauer, Lorenz C ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Breast cancer; Osteoclast; Osteoprotegerin; Syndecan 1

Indexed keywords

DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROGESTERONE RECEPTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SMALL INTERFERING RNA; SYNDECAN 1;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL FATE; CELL FUNCTION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; COCULTURE; DOSE RESPONSE; GENE SILENCING; MCF 7 CELL LINE; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84901653151     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2013.11.001     Document Type: Article

References (22)

1. Beauvais DM, Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004;2:3.
2. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77
3. Kato M, Saunders S, Nguyen H, Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 1995;6(5):559-76.
4. Manon-Jensen T, Itoh Y, Couchman Jr. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 2010;277(19):3876-89
5. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009;30(3):397-407.
6. Sun D, McAlmon KR, Davies JA, Bernfield M, Hay ED. Simultaneous loss of expression of syndecan-1 and E-cadherin in the embryonic palate during epithelial-mesenchymal transformation. Int J Dev Biol 1998;42(5):733-6.
7. SunH,Berquin IM,Owens RT,O'Flaherty JT, Edwards IJ. Peroxisome proliferator-Activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res 2008;68 (8):2912-9.
8. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003;98(3):474-83.
9. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004;67(1):11-8.
10. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, et al. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 2008;98(12):1993-8.
11. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000;95(2):388-92.
12. Dedes PG, Gialeli C, Tsonis AI, Kanakis I, Theocharis AD, Kletsas D, et al. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta 2012;1820(12):1926-39.
13. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100(8):3002-7.
14. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998;91 (8):2679-88.
15. Kelly T, Suva LJ, Nicks KM, MacLeod V, Sanderson RD. Tumor-derived syndecan-1 mediates distal cross-Talk with bone that enhances osteoclasto-genesis. J Bone Miner Res 2010;25(6):1295-304.
16. Pollow K, Grill HJ, Elger W, Christmann P, Manz B, Juchem M. Vergleichende Untersuchungen der synthetischen Antigestagene RU 38 486, ZK 98734 und ZK 98299 auf der Rezeptorebene. Arch Gynecol Obstet 1989;245:929-30.
17. Burbach BJ, Friedl A, Mundhenke C, Rapraeger AC. Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells. Matrix Biol 2003;22(2): 163-77.
18. Gotte M, Kersting C, Radke I, Kiesel L, Wulfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 2007;9(1):R8.
19. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S, et al. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 2000;25(3):329-32.
20. Beauvais DM, Burbach BJ, Rapraeger AC. The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol 2004;167(1):171-81.
21. Maeda T, DesoukyJ, Friedl A. Syndecan-1 expression by stromal fibroblasts promots breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006;25(9):1408-12.
22. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator ofthe aggressive tumor phenotype in myeloma. J Biol Chem 2008;283(47):32628-36.